A Jiangsu Hengrui Medicine Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. patent describes new fibroblast activation protein-α (FAP-α) inhibitors comprising a chelator and a radiolabeled compound potentially useful for the diagnosis and treatment of cancer.
